Advances in Medical and Surgical Management of Thyroid Cancer

Tampa, FL US
February 2, 2019 to February 3, 2019

Care of patients with thyroid nodules varies widely and differentiating benign nodules from malignancy requiring management remains a clinical challenge. Patients with thyroid nodules may be over- or under-treated for their disease.This program will provide clinicians with education on the latest updates to clinical practice guidelines to understand treatment algorithms for patients with thyroid cancer, as well as additional information about recently published clinical results, including advances in diagnosis, imaging, staging, and surveillance as well as surgical and systemic management of thyroid cancer. The application of the current clinical practice guidelines, including recent updates will also be discussed to improve overall patient care.


Target Audience

This program is specifically designed for endocrine surgeons, ENT and head and neck surgeons; radiologists; thyroidologists and endocrinologists; nuclear medicine physicians; nurse practitioners, physician assistants and sonographers.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Discuss evidence-based practices and current guidelines for the management of thyroid nodules and cancer
  • Evaluate recent advances in imaging and surveillance in thyroid cancer
  • Discuss clinical decision-making and the latest evidence for surgical and systemic management of thyroid cancer
Additional information
Available for MOC Points?: 
Practice Area: 
Course summary
Available credit: 
  • 13.00 AMA
  • 13.00 Attendance
  • 13.00 MOC
Course opens: 
Course expires: 
Event starts: 
02/02/2019 - 8:00am
Event ends: 
02/03/2019 - 2:30pm

Saturday, February 2, 2019
7:00- 7:50 am            Registration and Breakfast

7:50- 8:00 am            Welcome and Introduction

8:00- 8:30 am            Thyroid Nodule Guideline/TIRADS                                       

8:30- 9:00 am             Molecular Testing for Diagnosis

9:00- 9:30 am             Molecular Surgery Planning

9:30- 10:00 am           Surgeon’s Use of Ultrasound

10:00- 10:30 am         Coffee Break and Exhibits

10:30- 11:00 am         Extent of Initial Surgery (DTV vs. MTC)

11:00 am- Noon         Panel discussion

Noon- 1:00 pm           Lunch and Exhibits

1:00- 1:30 pm             What Endocrinologists and Surgeons Need to Know About Cytology and Histology

1:30- 2:00 pm             Active Surveillance vs. Immediate Surgery for Low Risk MicroPTC 

2:00- 2:30 pm             Active Surveillance vs. Immediate Surgery: A Surgeon’s View 

2:30- 3:00 pm             Practical Applications of PEI for Thyroid and Parathyroid Tumors

3:00- 3:30 pm             Coffee Break and Exhibits

3:30- 4:00 pm             Radioactive Iodine Therapy

4:00- 5:00 pm             Panel Discussion – Moderator: Robert Levine, MD, FACE, ECNU

5:00 pm                       Adjourn for the Day


Sunday, February 3, 2019

6:30- 7:00 am             Breakfast and Exhibits

7:00- 7:30 am             Perioperative Complications/Communication

7:30- 8:00 am             Post-Op Surveillance: US and TG 

8:00- 8:30 am             Dynamic Risk Stratification

8:30- 9:00 am             Locally Recurrent and Aggressive Disease – Surgical and XRT Considerations

9:00- 9:30 am             Coffee Break and Exhibits

9:30- 10:00 am            Genetic Profiling for Prognosis and Treatment

10:00- 10:30 am          Metastatic DTC: Local and Systemic Therapy

10:30- 11:30 am          Panel discussion – Moderator: Dev Abraham, MD, FACE, MRCP, ECNU

11:30 am- 12:30 pm      Lunch and Exhibits  

12:30- 2:30 pm               Cased Based Presentations – Moderator R. Mack Harrell, MD, FACP, FACE, ECNU

2:30 pm                          Adjourn


Renaissance Tampa International Plaza Hotel
4200 Jim Walter Blvd
Tampa, FL 33607
United States
+1 (813) 877-9200

Devaprabu Abraham, MD, MRCP, FACE, ECNU *
Professor of Medicine (Clinical),
Surgery and Pathology
Division of Endocrinology and ENT
Department of Medicine
University of Utah
Salt Lake City, UT

Naifa Busaidy, MD, FACP, FACE
Associate Professor, 
Director- Thyroid Nodule Clinic 
The University of Texas 
MD Anderson Cancer Center
Houston, TX

Denise Carneiro-Pla, MD
Professor of Surgery
Medical University of South Carolina
Charleston, SC

R. Mack Harrell, MD, FACP,  FACE, ECNU
Associate Clinical Professor
Nova Southeastern School of Medicine
Boca Raton, FL

Robert A. Levine, MD, FACE, ECNU *
Adjunct Assistant Professor of Endocrinology
Dartmouth Medical School
Director, Thyroid Center of New Hampshire
Nashua, NH

Mark A. Lupo, MD, FACE, ECNU *
Assistant Clinical Professor
Florida State University College of Medicine
Thyroid & Endocrine Center of Florida 
Sarasota, FL

Yuri Nikiforov, MD, PhD
Professor of Pathology
Vice Chair, Department of Pathology and Laboratory Medicine
Director, Division of Molecular and Genomic Pathology
University of Pittsburgh Medical Center 
Pittsburgh, PA

Greg Randolph, MD, FACS, FACE
Claire and John Bertucci Chair in Thyroid Surgical Oncology 
Professor of Otolaryngology Head and Neck Surgery
Harvard Medical School
Boston, MA

Ashok R. Shaha, MD, FACS
Attending Surgeon, Head and Neck Service Memorial Sloan-Kettering Cancer Center
Jatin P. Shah Chair in Head and Neck Surgery
Professor of Surgery 
Cornell University Medical College
New York, NY

R. Michael Tuttle, MD
Professor of Medicine, 
Clinical Director of Endocrinology Service
Memorial Sloan Kettering Cancer Center
New York, NY

* indicates planning committee member

Declaration of Disclosure and Conflicts of Interest

It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities. Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose. AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature.

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest. AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations.

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence.

AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

The following individuals have disclosed relevant financial relationships with commercial interests:

Naifa Busaidy                     Consulting Fees                                Eisai

                                                Consulting Fees                                Ioxo

                                                Research Grant                                 Novartis

Yuri Nikiforov                    Ownership                                          CBLPath/Sonic Health Care Company

All other faculty, planners and staff have disclosed no relevant financial relationships with commercial interests.




The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This course meets CME topic requirements for AACE ECNU Program

Please note that this activity is NOT the only route available to certification.

Available Credit

  • 13.00 AMA
  • 13.00 Attendance
  • 13.00 MOC
Please login or register to take this course.